Dr. Mohamed ElSayed is an accomplished leader with +25 years of experience spanning academia, biotechnology, and pharmaceutical organizations. He is a recognized expert in the development of small molecules, biologics, nucleic acids, and regenerative cell therapy.
Currently, he is the Oral Peptide Delivery Platform Leader at Eli Lilly & Company where he leads a cross-functional team of talented scientists that delivers the oral peptides portfolio. Prior to joining Lilly, Dr. ElSayed advised numerous pharmaceutical and biotechnology companies on challenging drug development programs while pursuing an academic career in parallel. He was a tenured professor at the University of Michigan where he established and led the Cellular Engineering and Nano-Therapeutics Laboratory. His research spanned multiple disciplines including biopharmaceutics, drug delivery, and material sciences with special emphasis on development of novel formulations for multiple therapeutic modalities. He constantly integrated technologies from disparate fields to develop innovative, robust, and scalable drug delivery platforms.
Dr. ElSayed received his B.Sc. and Ph.D. in Pharmaceutical Sciences from Cairo University, Egypt and the University of Maryland, Baltimore, respectively. He received +25 awards, contributed to 6 patents, co-authored +170 research articles and conference proceedings, and delivered +60 invited talks. Dr. ElSayed serves as chair of AAPS Pre-Formulation & Formulation Design/Development Community, a member of the Scientific Advisory Board of Boulder Peptide Society, and a member of the Editorial Office of Precision Nanomedicines and Journal of Pharmaceutical Sciences.